CN1547475A - 采用电子转移试剂的磷酸酯衍生物进行皮肤治疗 - Google Patents
采用电子转移试剂的磷酸酯衍生物进行皮肤治疗 Download PDFInfo
- Publication number
- CN1547475A CN1547475A CNA028148185A CN02814818A CN1547475A CN 1547475 A CN1547475 A CN 1547475A CN A028148185 A CNA028148185 A CN A028148185A CN 02814818 A CN02814818 A CN 02814818A CN 1547475 A CN1547475 A CN 1547475A
- Authority
- CN
- China
- Prior art keywords
- phosphate ester
- electron transfer
- transfer agents
- total weight
- tocopherol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012992 electron transfer agent Substances 0.000 title claims abstract description 75
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 title abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 230000002500 effect on skin Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 144
- 208000024891 symptom Diseases 0.000 claims abstract description 38
- 239000012049 topical pharmaceutical composition Substances 0.000 claims abstract description 32
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 189
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 160
- -1 tocopherol phosphate ester Chemical class 0.000 claims description 154
- 229910019142 PO4 Inorganic materials 0.000 claims description 136
- 239000010452 phosphate Substances 0.000 claims description 135
- 229930003799 tocopherol Natural products 0.000 claims description 134
- 239000011732 tocopherol Substances 0.000 claims description 134
- 235000010384 tocopherol Nutrition 0.000 claims description 133
- 229960001295 tocopherol Drugs 0.000 claims description 133
- 206010000496 acne Diseases 0.000 claims description 95
- 206010015150 Erythema Diseases 0.000 claims description 91
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 86
- 231100000321 erythema Toxicity 0.000 claims description 84
- 235000019260 propionic acid Nutrition 0.000 claims description 81
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 79
- 238000011282 treatment Methods 0.000 claims description 75
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 72
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 64
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 57
- 230000004054 inflammatory process Effects 0.000 claims description 56
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 56
- 206010061218 Inflammation Diseases 0.000 claims description 55
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 35
- 230000003115 biocidal effect Effects 0.000 claims description 34
- 208000017520 skin disease Diseases 0.000 claims description 32
- 206010048768 Dermatosis Diseases 0.000 claims description 31
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 27
- 229920002125 Sokalan® Polymers 0.000 claims description 26
- 206010040954 Skin wrinkling Diseases 0.000 claims description 23
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 21
- 208000027418 Wounds and injury Diseases 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 20
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 20
- 235000010323 ascorbic acid Nutrition 0.000 claims description 19
- 239000011668 ascorbic acid Substances 0.000 claims description 19
- 229960005070 ascorbic acid Drugs 0.000 claims description 19
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 19
- 230000037303 wrinkles Effects 0.000 claims description 19
- 230000002421 anti-septic effect Effects 0.000 claims description 18
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 17
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 17
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 17
- 229940035936 ubiquinone Drugs 0.000 claims description 17
- 229960001631 carbomer Drugs 0.000 claims description 16
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 16
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 14
- 206010042496 Sunburn Diseases 0.000 claims description 14
- 239000004098 Tetracycline Substances 0.000 claims description 14
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 14
- 229960002180 tetracycline Drugs 0.000 claims description 14
- 235000019364 tetracycline Nutrition 0.000 claims description 14
- 229930101283 tetracycline Natural products 0.000 claims description 14
- 150000003522 tetracyclines Chemical class 0.000 claims description 14
- 201000004624 Dermatitis Diseases 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000003410 keratolytic agent Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 239000000516 sunscreening agent Substances 0.000 claims description 12
- 229930003802 tocotrienol Natural products 0.000 claims description 12
- 239000011731 tocotrienol Substances 0.000 claims description 12
- 235000019148 tocotrienols Nutrition 0.000 claims description 12
- 230000000699 topical effect Effects 0.000 claims description 12
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 11
- 230000000475 sunscreen effect Effects 0.000 claims description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 239000002585 base Substances 0.000 claims description 10
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 10
- 229960002216 methylparaben Drugs 0.000 claims description 10
- 229960004889 salicylic acid Drugs 0.000 claims description 10
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 9
- 230000002924 anti-infective effect Effects 0.000 claims description 9
- 229960005287 lincomycin Drugs 0.000 claims description 9
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 9
- 206010053615 Thermal burn Diseases 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 8
- 239000011719 vitamin A Substances 0.000 claims description 8
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 8
- FVOOPOSZDXPIMS-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-2-ol Chemical class C1=CC=C2OC(O)CCC2=C1 FVOOPOSZDXPIMS-UHFFFAOYSA-N 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 229960003276 erythromycin Drugs 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 238000005286 illumination Methods 0.000 claims description 7
- 201000004700 rosacea Diseases 0.000 claims description 7
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- 241001597008 Nomeidae Species 0.000 claims description 6
- 208000012641 Pigmentation disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 6
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 5
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 claims description 5
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 229940073669 ceteareth 20 Drugs 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- 229960003415 propylparaben Drugs 0.000 claims description 5
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 5
- 208000003014 Bites and Stings Diseases 0.000 claims description 4
- 208000001840 Dandruff Diseases 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940008099 dimethicone Drugs 0.000 claims description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 4
- 208000007565 gingivitis Diseases 0.000 claims description 4
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 claims description 4
- 230000019612 pigmentation Effects 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 claims description 3
- 229960001083 diazolidinylurea Drugs 0.000 claims description 3
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- 206010003402 Arthropod sting Diseases 0.000 claims description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 2
- 208000003643 Callosities Diseases 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- ZVGCGHVMJAECEG-UHFFFAOYSA-N Chinol Natural products COC1=C(O)C(C)=C(C)C(O)=C1OC ZVGCGHVMJAECEG-UHFFFAOYSA-N 0.000 claims description 2
- 241001517488 Clavus Species 0.000 claims description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 2
- 206010051246 Photodermatosis Diseases 0.000 claims description 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 2
- 150000001746 carotenes Chemical class 0.000 claims description 2
- 235000005473 carotenes Nutrition 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 201000004196 common wart Diseases 0.000 claims description 2
- 229960002061 ergocalciferol Drugs 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 230000008845 photoaging Effects 0.000 claims description 2
- 235000019175 phylloquinone Nutrition 0.000 claims description 2
- 239000011772 phylloquinone Substances 0.000 claims description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 2
- 229960001898 phytomenadione Drugs 0.000 claims description 2
- 201000004303 plantar wart Diseases 0.000 claims description 2
- 230000006340 racemization Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 201000010153 skin papilloma Diseases 0.000 claims description 2
- 229960001727 tretinoin Drugs 0.000 claims description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 2
- 235000001892 vitamin D2 Nutrition 0.000 claims description 2
- 239000011653 vitamin D2 Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 12
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 150000002085 enols Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000002917 insecticide Substances 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 229940084106 spermaceti Drugs 0.000 claims 1
- 239000012177 spermaceti Substances 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 description 112
- 210000003491 skin Anatomy 0.000 description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
- 238000012360 testing method Methods 0.000 description 39
- 239000012153 distilled water Substances 0.000 description 36
- 230000006378 damage Effects 0.000 description 33
- 239000007788 liquid Substances 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 210000002615 epidermis Anatomy 0.000 description 30
- 239000006071 cream Substances 0.000 description 29
- 238000009472 formulation Methods 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 27
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000000499 gel Substances 0.000 description 22
- 230000001815 facial effect Effects 0.000 description 21
- 230000008859 change Effects 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000008367 deionised water Substances 0.000 description 15
- 229910021641 deionized water Inorganic materials 0.000 description 15
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical class CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 14
- 206010025421 Macule Diseases 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 229930003427 Vitamin E Natural products 0.000 description 14
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 229940083037 simethicone Drugs 0.000 description 14
- 235000019165 vitamin E Nutrition 0.000 description 14
- 239000011709 vitamin E Substances 0.000 description 14
- 229940046009 vitamin E Drugs 0.000 description 14
- 229920004511 Dow Corning® 200 Fluid Polymers 0.000 description 13
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 13
- 230000006872 improvement Effects 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 230000003780 keratinization Effects 0.000 description 11
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 10
- 239000000084 colloidal system Substances 0.000 description 10
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229910052567 struvite Inorganic materials 0.000 description 10
- 101000679525 Homo sapiens Two pore channel protein 2 Proteins 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 102100022609 Two pore channel protein 2 Human genes 0.000 description 9
- 206010000269 abscess Diseases 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 150000003431 steroids Chemical class 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 238000012805 post-processing Methods 0.000 description 8
- 210000002374 sebum Anatomy 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000007766 cera flava Substances 0.000 description 7
- 210000000589 cicatrix Anatomy 0.000 description 7
- 229960002227 clindamycin Drugs 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 230000001804 emulsifying effect Effects 0.000 description 7
- 210000004209 hair Anatomy 0.000 description 7
- 210000003780 hair follicle Anatomy 0.000 description 7
- 238000009434 installation Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 239000002480 mineral oil Substances 0.000 description 7
- 235000010446 mineral oil Nutrition 0.000 description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 7
- 238000002203 pretreatment Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000008117 stearic acid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- PDRZOMUQUZBNKV-MKOSUFFBSA-N [(2e,4e,6z,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] dihydrogen phosphate Chemical compound OP(=O)(O)OC\C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C PDRZOMUQUZBNKV-MKOSUFFBSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 230000002207 retinal effect Effects 0.000 description 6
- 125000002769 thiazolinyl group Chemical group 0.000 description 6
- 239000007762 w/o emulsion Substances 0.000 description 6
- 239000004342 Benzoyl peroxide Substances 0.000 description 5
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 5
- 208000003351 Melanosis Diseases 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 235000019400 benzoyl peroxide Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000254 damaging effect Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000012797 qualification Methods 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000234295 Musa Species 0.000 description 4
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000033809 Suppuration Diseases 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000010378 sodium ascorbate Nutrition 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 229940111630 tea tree oil Drugs 0.000 description 4
- 239000010677 tea tree oil Substances 0.000 description 4
- 229940005605 valeric acid Drugs 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 3
- 208000002260 Keloid Diseases 0.000 description 3
- 206010023330 Keloid scar Diseases 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000003093 cationic surfactant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000000640 hydroxylating effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 210000001117 keloid Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 3
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 201000008261 skin carcinoma Diseases 0.000 description 3
- 230000036559 skin health Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- FXKDMPREBVBOMS-UHFFFAOYSA-N [O].C1OC=CC=C1 Chemical compound [O].C1OC=CC=C1 FXKDMPREBVBOMS-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000005340 bisphosphate group Chemical group 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000037312 oily skin Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229950000516 padimate Drugs 0.000 description 2
- LXTZRIBXKVRLOA-UHFFFAOYSA-N padimate a Chemical compound CCCCCOC(=O)C1=CC=C(N(C)C)C=C1 LXTZRIBXKVRLOA-UHFFFAOYSA-N 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- ZPLUZNXSYCCJOE-UHFFFAOYSA-N phosphoric acid;propan-2-one Chemical compound CC(C)=O.OP(O)(O)=O ZPLUZNXSYCCJOE-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 2
- 150000003505 terpenes Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
- REUDPRVPPDWOKE-UHFFFAOYSA-N 1,1'-biphenyl;1h-imidazole Chemical class C1=CNC=N1.C1=CC=CC=C1C1=CC=CC=C1 REUDPRVPPDWOKE-UHFFFAOYSA-N 0.000 description 1
- KBKGPMDADJLBEM-UHFFFAOYSA-N 1-(4-pentylphenyl)ethanone Chemical compound CCCCCC1=CC=C(C(C)=O)C=C1 KBKGPMDADJLBEM-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- GRXHGLGXNALPFR-UHFFFAOYSA-N 2-hydroxyicosan-3-one Chemical compound CCCCCCCCCCCCCCCCCC(=O)C(C)O GRXHGLGXNALPFR-UHFFFAOYSA-N 0.000 description 1
- CNXZMGRWEYQCOQ-UHFFFAOYSA-N 2-methoxy-3-phenylprop-2-enoic acid Chemical compound COC(C(O)=O)=CC1=CC=CC=C1 CNXZMGRWEYQCOQ-UHFFFAOYSA-N 0.000 description 1
- WHSXTWFYRGOBGO-UHFFFAOYSA-N 3-methylsalicylic acid Chemical compound CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 201000004625 Acrodermatitis Diseases 0.000 description 1
- 206010068388 Actinic elastosis Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 206010004950 Birth mark Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 241000186984 Kitasatospora aureofaciens Species 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010059605 Necrobiosis Diseases 0.000 description 1
- 208000015906 Necrobiotic disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187399 Streptomyces lincolnensis Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 241000317530 Typhonodorum lindleyanum Species 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- SZAMSYKZCSDVBH-CLFAGFIQSA-N [(z)-octadec-9-enyl] (z)-docos-13-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCCCCCCCC\C=C/CCCCCCCC SZAMSYKZCSDVBH-CLFAGFIQSA-N 0.000 description 1
- VUNHSSYEAVRURP-UHFFFAOYSA-N [C].[O].[P] Chemical compound [C].[O].[P] VUNHSSYEAVRURP-UHFFFAOYSA-N 0.000 description 1
- UHXWLHYMUGRLKG-UHFFFAOYSA-N [Mg].O[Si](O)(O)O Chemical compound [Mg].O[Si](O)(O)O UHXWLHYMUGRLKG-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- CMDKPGRTAQVGFQ-RMKNXTFCSA-N cinoxate Chemical compound CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1 CMDKPGRTAQVGFQ-RMKNXTFCSA-N 0.000 description 1
- 229960001063 cinoxate Drugs 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 229960001275 dimeticone Drugs 0.000 description 1
- 229960004960 dioxybenzone Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical class CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- UIVLIZYJHYWOBB-UHFFFAOYSA-N ethane-1,2-diol;hex-1-ene Chemical group OCCO.CCCCC=C UIVLIZYJHYWOBB-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 101150107144 hemC gene Proteins 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000029774 keratinocyte migration Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- SCQAMMSHDNVWMQ-UHFFFAOYSA-N methyl 2-hydroxybenzoate;propane-1,2-diol Chemical compound CC(O)CO.COC(=O)C1=CC=CC=C1O SCQAMMSHDNVWMQ-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 125000004355 nitrogen functional group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- WVJVHUWVQNLPCR-UHFFFAOYSA-N octadecanoyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCC WVJVHUWVQNLPCR-UHFFFAOYSA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 229940120511 oleyl erucate Drugs 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940057874 phenyl trimethicone Drugs 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 description 1
- 229960005009 rolitetracycline Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000002129 tachyphylactic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
十二烷基亚氨基二丙酸生育酚磷酸酯(30%)Carbomer ultrez 3%防腐剂DMDMH三乙醇胺99%D&C red33(0.4)%蒸馏水 | 10.0012.000.100.250.0277.63 |
01234 | 面部皮肤不需要完全干净。少数散布的痤疮或丘疹可以存在,但它们只在近距离检查时方可看到。存在痤疮或小丘疹,在1-3英尺远可以看到。涉及到大约1/4的面部区域,有小的丘疹及痤疮。可以看到少数脓疮或大的显著的丘疹。涉及大约30%(26-49%)的面部区域,有小的丘疹(13-20)以及小的痤疮。可以看到少数脓疮或大的显著的丘疹涉及面部区域的大约1/2,有小的丘疹和大的或小的痤疮。通常有少数脓 |
5678 | 疮或大的显著的丘疹(如果损伤通常较大,受试者可能有4级严重度,尽管涉及的面部区域不到1/2)。涉及超过1/2(51-74%)的面部区域,有大的及小的丘疹和痤疮(如果严重区域大,较少的面部区域是允许的)。通常存在中等数量的脓疮,其中部分可能较大。涉及大约3/4的面部区域,并有脓疮和/或大的破损的痤疮。(如果严重的区域大,较少的面部区域是允许的。)通常有大量的脓疮,其中部分可能较大。涉及>75%但少于85%的面部区域,其中大部分损伤是丘疹及大的破损的痤疮。脓疮可能较大且显著。涉及实际上全部的面部区域。通常可见大的显著的脓疮。损伤通常是高度炎症性的。可能存在其它类型的痤疮(例如球状的,包括窦状及囊状类型)。 |
01234 | 无很轻(很难感觉到红肿/水肿)轻度(可感觉到,但红肿/水肿轻微)中度(明显的红肿/水肿)重度(显著的,一致的红肿/水肿) |
01234 | 无干燥/鳞屑轻微干燥(细粉末状,很难感觉到)轻度/中度干燥(一定数量的粉末状,有一些小的边界)中度干燥(边界比大部分分级的位点升高,有一些大的、松散贴附的鳞片)严重干燥(大部分分级区域上有大的、松散贴附的鳞片,可能有裂隙) |
高度红斑 | 0=平坦0=无 | 10=很高10=严重 |
TPC2 | 对照 | |||||||
基线访问2 | 第2天访问3 | 第3天访问4 | 第6天访问5 | 基线访问2 | 第2天访问3 | 第3天访问4 | 第6天访问5 | |
周围的红斑 | 0.90 | 0.40+ | 0.60+ | 0.45+ | 1.00 | 0.20+ | 0.40+ | 0.55+ |
周围的鳞片化 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
损伤性隆起 | 4.05 | 3.56+ | 2.80+ | 0.94+ | 4.08 | 3.88 | 3.24+ | 2.36+ |
损伤性红斑 | 3.93 | 3.55+ | 2.84+ | 1.08+ | 4.14 | 3.89+ | 3.15+ | 2.31+ |
访问2(基线) | 访问3(第2天) | 访问4(第3天) | 访问5(第6天) | ||
TPC2 | 丘疹 | 20 | 20 | 19 | 11 |
斑疹 | 0 | 0 | 1 | 9 | |
对照 | 丘疹 | 20 | 20 | 20 | 19 |
斑疹 | 0 | 0 | 0 | 1 |
受试者号码 | 种族 | 出生日期 | Fitzpatrick分类 |
002 | 高加索 | 05/19/68 | II |
003 | 高加索 | 12/21/58 | II |
004 | 高加索 | 05/03/78 | II |
006 | 越南 | 04/20/63 | II |
007 | 高加索 | 01/24/65 | II |
90/1(3%十二烷基亚氨基二丙酸生育酚磷酸酯) | 按下面的实施例3制备的组分 |
90/2(1%十二烷基亚氨基二丙酸生育酚磷酸酯) | 实施例3的组分用水稀释到1%的活性成分 |
90/3(0.5%十二烷基亚氨基二丙酸生育酚磷酸酯) | 实施例3的组分用水稀释到0.5%的活性成分 |
90/4(3%生育酚乙酸酯) | 实施例3的组分用生育酚乙酸酯代替十二烷亚氨基二丙酸生育酚磷酸酯 |
90/5(安慰剂) | 实施例3的组分中不含十二烷亚氨基二丙酸生育酚磷酸酯 |
0.1%类固醇霜-参考品对照 | 商品化的抗炎症产品,其中1克霜剂中含有1mg的莫米松糠酸盐,霜剂的基质是己烯乙二醇、磷酸、丙烯乙二醇硬脂酸盐、steryl乙醇和cetaareth-20、二氧化钛、辛烯基琥珀酸盐铝淀粉、白蜡、白石蜡油及纯净水 |
Banana BoatTM Aloe Vera凝胶-参考品对照 | 美国Sun Pharmaceuticals公司的商业化产品 |
无剂量的贴—未处理的对照 |
前处理评价 | ||||||||
红斑的临床打分 | 颜色仪(a*) | |||||||
第7天 | 第8天 | 第9天 | 第10天 | 第7天 | 第8天 | 第9天 | 第10天 | |
90/1 | 1.10 | 0.80 | 0.30 | 0.30 | 9.13 | 9.40 | 7.66 | 8.35 |
90/2 | 1.10 | 0.80 | 0.40 | 0.40 | 11.69 | 8.69 | 8.17 | 8.42 |
90/3 | 1.30 | 0.90 | 0.60 | 0.50 | 12.04 | 10.11 | 9.87 | 9.47 |
Banana BoatAloe Vera凝胶 | 1.60 | 1.20 | 0.70 | 0.70 | 12.31 | 9.02 | 9.04 | 8.45 |
90/4 | 1.50 | 1.10 | 0.70 | 0.70 | 11.81 | 10.42 | 9.08 | 9.82 |
90/5 | 1.60 | 1.20 | 0.90 | 0.90 | 13.57 | 11.32 | 9.66 | 10.52 |
类固醇霜 | 1.10 | 0.80 | 0.60 | 0.50 | 11.87 | 10.45 | 10.19 | 9.53 |
无剂量的贴剂 | 1.60 | 1.20 | 0.90 | 0.80 | 11.64 | 10.32 | 9.64 | 9.61 |
后处理评价 | ||||||||
红斑的临床打分 | 颜色仪(a*) | |||||||
第4天 | 第5天 | 第6天 | 第7天 | 第4天 | 第5天 | 第6天 | 第7天 | |
90/1 | 2.60 | 1.70 | 1.20 | 1.10 | 12.23 | 10.98 | 11.45 | 10.54 |
90/2 | 2.60 | 1.70 | 1.40 | 1.20 | 14.94 | 13.36 | 9.20 | 8.92 |
90/3 | 2.60 | 1.90 | 1.70 | 1.50 | 13.67 | 11.62 | 10.64 | 10.75 |
Banana Boat AloeVera凝胶 | 2.80 | 2.50 | 2.63 | 1.80 | 13.54 | 12.00 | 12.59 | 12.60 |
90/4 | 2.60 | 2.70 | 2.50 | 1.80 | 15.09 | 13.12 | 12.07 | 10.30 |
90/5 | 2.80 | 2.80 | 2.50 | 1.80 | 14.99 | 12.11 | 11.03 | 9.68 |
类固醇霜 | 1.40 | 1.10 | 0.80 | 0.80 | 9.45 | 6.67 | 7.57 | 8.55 |
无剂量的贴剂 | 2.60 | 2.50 | 2.25 | 1.75 | 14.84 | 10.76 | 8.20 | 9.22 |
成分 | %WW | 供应商 | |
A) | 十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 10.00 | Vital Personal CareSpecialities Inc. |
Ultrez卡波姆-3% | 12.00 | B.F.Goodrich | |
蒸馏水 | q.s.100% | ||
B) | 三乙醇胺-99% | 0.25% | Union Carbide |
含防腐剂和颜料的蒸馏水 | 40.13 |
A相 | W/W |
去离子水 | 61.95% |
甘油EDTA三钠卡波姆(Carbopol Ultrez 10)2十二烷基亚氨基二丙酸生育酚磷酸酯1 | 5.000.050.507.50 |
B相 | |
Cetearyl乙醇(和)Ceteareth-20(Phoenoxol T)3硬脂酸甘油酯(Emerest 2400)4豆蔻酸异丙酯(Pelemol IPM)3十六烷基己酸乙酯(Pelemol 168)3isocetyl异十六(烷)基山嵛酸酯(Pelemol ICB)3异十六烷基榆树酸酯(Cetiol J-600)4二甲聚硅氧烷(Dow 200,100 cSt.)5 | 2.001.005.003.503.503.000.50 |
C相 | |
去离子水三乙醇胺(99%) | 5.000.50 |
D相 | |
尼泊金甲酯丙二醇(和)Diazolidinyl尿素(和)尼泊金丙酯(Germaben II)6 | 1.00 |
100.00% |
产品A(n=7) | 产品B(n=3) | |||||
基线 | 第4周 | 第8周 | 基线 | 第4周 | 第8周 | |
刺激红斑 | 0.14 | 0.00 | 0.14 | 0.33 | 0.33 | 0.33 |
肿胀 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
鳞片化 | 0.00 | 0.00 | 0.00 | 0.00 | 0.67 | 0.00 |
灼伤 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
蛰刺 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
瘙痒 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
紧度 | 0.14 | 0.00 | 0.00 | 0.00 | 0.33 | 0.00 |
麻刺 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
皮疹 | 0.00 | 0.00 | 0.14 | 0.00 | 0.00 | 0.00 |
疗效细线 | 4.07 | 3.14↓ | 2.43↓ | 3.50 | 3.33 | 3.25 |
皱纹 | 3.39 | 2.96↓ | 2.36↓ | 3.67 | 3.58 | 3.25 |
毛孔大小 | 6.18 | 5.57 | 4.68↓ | 4.25 | 4.08 | 4.00 |
斑驳色素沉着 | 3.82 | 3.57 | 3.14 | 3.50 | 3.50 | 3.58 |
皮肤总体外观 | 5.46 | 4.68↓ | 3.68↓ | 6.67 | 6.58 | 6.17 |
掐捏回复(秒) | 1.89 | 1.56↓ | 1.46↓ | 1.87 | 1.94 | 1.81 |
产品A(n=7) | 产品B(n=3) | |||
第4周 | 第8周 | 第4周 | 第8周 | |
与研究开始时相比对细线和皱纹的总体外观的改善 | 4.00 | 4.00 | 2.67 | 3.33 |
与研究开始时相比产品对皮肤颜色不均一的改善 | 4.00 | 3.71 | 3.00 | 3.33 |
与研究开始时相比产品使我的毛孔缩小的程度 | 4.00 | 3.71 | 3.33 | 3.00 |
成分 | w/w百分比 |
十六烷基醇C12-15乙醇苯甲酸酯羟基茴香醚丁酸酯PEG-100硬脂酸酯水,去离子水或蒸馏水丙二醇十二烷基亚氨基二丙酸生育酚磷酸酯丙酮 | 0.7550.10.2570.43.010.510.0 |
成分 | W/w百分比 |
十六烷基硬脂酰乙醇酯C12-15乙醇苯甲酸酯羟基茴香醚丁酸酯PEG-100硬脂酸酯水,去离子水或蒸馏水丙二醇十二烷基亚氨基二丙酸生育酚磷酸酯丙酮 | 1.2550.010.8569.1310.510 |
成分 | W/w百分比 |
水,去离子水或蒸馏水Veegum.RTM.(R.T. Vanderbilt Co.)羧基乙烯基聚合物(酸)二异丙醇胺乙醇,200度十二烷基亚氨基二丙酸生育酚磷酸酯 | 50.651.510.7530.115 |
成分 | W/w百分比 |
十二烷基亚氨基二丙酸生育酚磷酸酯四环素乙醇PEG-8癸酸酯胶体mg硅酸铝羟乙基甲基纤维素柠檬酸水 | 2022062.50.750.05适量 |
成分 | W/w百分比 |
十二烷基亚氨基二丙酸生育酚磷酸酯维生素ACarbomer.RTM.940氢氧化钠调节至需要的pH水 | 150.51适量适量 |
成分 | %w/w | 供应商 | |
A) | Brij 72(POE 2硬脂醚)Emerest 132(硬脂酸)Pelemol PDD(丙二醇二辛酸酯/辛酸酯)Drakeol 9(LT矿物油)Brij 721(POE 21硬脂醚)辛基对甲氧基肉桂酸Benzophenane-3Dicorning 200 Fluid(二甲硅油)Propyl Paraben | 0.52.010.09.01.07.02.01.00.1 | Unichema AmericasCognisPhoenixPenrecoUniqema Americas |
B) | Cabopol Ultrez 10混悬液3%水 | 5.010.0 | |
C) | TEA99%蒸馏水甲基paraben十二烷基亚氨基二丙酸生育酚磷酸酯-40%,含DMDMH蒸馏水适量 | 1.210.00.257.533.45 |
成分 | %w/w | 供应商 | |
A) | 山梨醇USP40%十二烷基亚氨基二丙酸生育酚磷酸酯 | 15.07.5 | |
B) | 甘油USP 96%三氯生糖精钠USP 40/60目Veegum D-颗粒薄荷油Stepanol WA/100(十二烷基硫酸钠) | 10.00.30.22.01.12.2 | Firmenich |
C) | Veegum HF-6%(Ag/Al硅酸盐)蓝色1号FD+C(0.6%) | 16.640.06 | |
D) | Na-CMC 7 H 5% | 45.0 |
成分 | %WW | 供应商 |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 5.0 | VPCS |
抗坏血酸钠磷酸酯(SAP)95-99% | 1.5 | BASF |
羟乙基纤维素 | 0.5 | HERCULES |
含防腐剂、颜料的去离子水 | q.s.ad 100% |
成分 | %WW | 供应商 |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 3.0 | VPCS |
抗坏血酸钠磷酸酯(SAP)99% | 2.1 | BASF |
羧甲基纤维素钠-7 HF 5% | 35.0 | DOW |
含防腐剂、颜料的去离子水 | q.s.ad 100% |
成分 | %WW | 供应商 |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 7.0 | VPCS |
十二烷基亚氨基二丙酸抗坏血酸磷酸酯(LAAP)6% | 15.0 | VPCS |
Natrasol 250 HHR-4% | 42.00 | |
防腐剂,颜料、芳香剂DEI,去离子水 | q.s.ad 100% |
成分 | %WW | 供应商 | |
A) | Brij 72-POE 2硬脂醚 | 0.5 | Uniqema Americas |
Emerest 132(硬脂酸) | 2.0 | Cognis | |
Pelemol(PDD)-(丙二醇二辛酸酯/辛酸酯) | 10.0 | Phoenix | |
Drake oil 9(LT矿物油) | 9.0 | Penreco | |
Brij 721(POE 21硬脂醚) | 1.0 | Uniqema Americas | |
辛基对甲氧基肉桂酸 | 7.0 | ISP | |
Benzophenane-3 | 2.0 | ISP | |
Dow Corning 200 Fluid(二甲硅油) | 1.0 | Dow Corning | |
Propyl Paraben | 0.1 | Clariant Corp. | |
B) | Cabopol Ultrez 10混悬液3% | 5.0 | B.F.Goodrich |
蒸馏水 | 7.5 | ||
C) | TEA99% | 1.2 | Union Carbide |
甲基paraben | 0.25 | Clariant Corp. | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 10.0 | VPCS | |
蒸馏水 | q.s.100% |
成分 | %WW | 供应商 | |
A) | Brij 72-POE 2硬脂醚 | 0.5 | Uniqema Americas |
Emerest 132-硬脂酸 | 2.0 | Cognis | |
Pelemol PDD-丙二醇二辛酸酯/辛酸酯 | 10.0 | Phoenix | |
Drake oil 9-LT矿物油 | 9.0 | Penreco | |
Brij 721-POE 21硬脂醚 | 1.0 | Uniqema Americas | |
辛基对甲氧基肉桂酸 | 5.0 | ISP | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
Propyl Paraben | 0.1 | Clariant Corp. | |
B) | Cabopol Ultrez 10混悬液3%Escalol 577 | 5.05.0 | B.F.GoodrichISP |
蒸馏水 | 7.5 | ||
C) | TEA99% | 1.2 | Union Carbide |
蒸馏水 | 12.5 | ||
甲基paraben | 0.25 | Clariant Corp. | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 10.0 | VPCS | |
蒸馏水 | q.s.100% |
成分 | %WW | 供应商 | |
A) | Brij 72-POE 2硬脂醚 | 0.5 | Uniqema Americas |
Emerest 132-硬脂酸 | 2.0 | Cognis | |
Pelemol PDD-丙二醇二辛酸酯/辛酸酯 | 10.0 | Phoenix | |
Drake oil 9-LT矿物油 | 9.0 | Penreco | |
Brij 721-POE 21硬脂醚 | 1.0 | Uniqema Americas | |
Escalol 567 | 6.0 | ISP | |
Benzophenone-3 | 2.0 | ISP | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
Propyl Paraben | 0.1 | Clariant Corp. | |
B) | Cabopol Ultrez 10混悬液3% | 5.0 | B.F.Goodrich |
蒸馏水 | 7.5 | ||
C) | TEA-99% | 1.2 | Union Carbide |
蒸馏水 | 12.5 | ||
甲基paraben | 0.25 | Clariant Corp. | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 10.0 | VPCS | |
蒸馏水 | q.s.100% |
成分 | %WW | 供应商 | |
A) | Brij 72-POE 2硬脂醚 | 0.5 | Uniqema Americas |
Emerest 132-硬脂酸 | 2.0 | Cognis | |
Pelemol PDD-丙二醇二辛酸酯/辛酸酯 | 10.0 | Phoenix | |
Drake oil 9-LT矿物油 | 9.0 | Penreco | |
Brij 721-POE 21硬脂醚 | 1.0 | Uniqema Americas | |
Escalol 587 | 5.0 | ISP | |
Benzophenone-3 | 2.0 | ISP | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
Propyl Paraben | 0.1 | Clariant Corp. | |
B) | Cabopol Ultrez 10混悬液3% | 5.0 | B.F.Goodrich |
蒸馏水 | 7.5 | ||
C) | TEA-99% | 1.2 | Union Carbide |
蒸馏水 | 12.5 | ||
甲基paraben | 0.25 | Clariant Corp. | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 10.0 | VPCS | |
蒸馏水 | q.s.100% |
成分 | %WW | 供应商 | |
A) | Brij 72-POE 2硬脂醚 | 0.5 | Uniqema Americas |
Emerest 132-硬脂酸 | 2.0 | Cognis | |
Pelemol PDD-丙二醇二辛酸酯/辛酸酯 | 10.0 | Phoenix | |
Drake oil 9-LT矿物油 | 9.0 | Penreco | |
Brij 721-POE 21硬脂醚 | 1.0 | Uniqema Americas | |
Escalol 557 | 5.0 | ISP | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
Propyl Paraben | 0.1 | Clariant Corp. | |
B) | Cabopol Ultrez 10混悬液3% | 5.0 | B.F.Goodrich |
蒸馏水 | 7.5 | ||
C) | TEA-99% | 1.2 | Union Carbide |
TiO2 | 2.0 | Tayka | |
蒸馏水 | 12.5 | ||
甲基paraben | 0.25 | Clariant Corp. | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 10.0 | VPCS | |
蒸馏水 | q.s.100% |
成分 | %WW | 供应商 | |
A) | Brij 72-POE 2硬脂醚 | 0.5 | Uniqema Americas |
Emerest 132-硬脂酸 | 2.0 | Cognis | |
Pelemol PDD-丙二醇二辛酸酯/辛酸酯 | 10.0 | Phoenix | |
Drake oil 9-LT矿物油 | 9.0 | Penreco | |
Brij 721-POE 21硬脂醚 | 1.0 | Uniqema Americas | |
Escalol 597 | 10.0 | ISP | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
Propyl Paraben | 0.1 | Clariant Corp. | |
B) | Cabopol Ultrez 10-混悬液3% | 5.0 | B.F.Goodrich |
蒸馏水 | 7.5 | ||
C) | TEA-99% | 1.2 | Union Carbide |
氧化锌 | 2.0 | Z-COTE--BASF | |
蒸馏水 | 12.5 | ||
甲基paraben | 0.25 | Clariant Corp. | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 10.0 | VPCS | |
蒸馏水 | q.s.100% |
成分 | %WW | 供应商 | |
A) | Cetiol OE-二-N-辛基醚 | 23.0 | Cognis |
Dehymuls PGPH | 5.0 | Cognis | |
蜂蜡 | 0.5 | Stahl & Pitsch | |
硬脂酸锌 | 0.5 | Whittaker | |
padimate 0 | 7.0 | ISP | |
Avobenzone | 2.0 | ||
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
B) | 硫酸镁 | 0.3 | |
甘油96% | 5.0 | Dow Chemical | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 6.67 | VPCS | |
抗坏血酸钠磷酸酯(SAP)-95-99% | 1.0 | BASF | |
蒸馏水 | q.s.100% | ||
C) | Germall II | 1.0 | Sutton Lab,ISP |
成分 | %WW | 供应商 | |
A) | Cetiol OE-Di-二-N-辛基醚 | 23.0 | Cognis |
Dehymuls PGPH | 5.0 | Cognis | |
蜂蜡 | 0.5 | Stahl & Pitsch | |
硬脂酸锌 | 0.5 | Whittaker | |
三乙醇胺水杨酸盐 | 7.0 | ISP | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
B) | 硫酸镁 | 0.3 | |
MT 150 W | 5.0 | Tayca | |
甘油96% | 5.0 | Dow Chemical | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 3.33 | VPCS | |
十二烷基亚氨基二丙酸抗坏血酸磷酸酯-6% | 33.33 | VPCS | |
抗坏血酸钠磷酸酯(SAP)-95-99% | 1.0 | BASF | |
蒸馏水 | q.s.100% | ||
C) | Germall II | 1.0 | Sutton Lab,ISP |
成分 | %WW | 供应商 | |
A) | Cetiol OE-Di-二-N-辛基醚 | 23.0 | Cognis |
Dehymuls PGPH | 5.0 | Cognis | |
蜂蜡 | 0.5 | Stahl & Pitsch | |
硬脂酸锌 | 0.5 | Whittaker | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
B) | 硫酸镁 | 0.3 | |
氧化锌 | 5.0 | Z-COTE-BASF | |
甘油96% | 5.0 | Dow Chemical | |
十二烷基亚氨基二丙酸生育酚磷酸酯-6% | 10.0 | VPCS | |
蒸馏水 | q.s.100% | ||
C) | Germall II | 1.0 | Sutton Lab,ISP |
成分 | %WW | 供应商 | |
A) | Cetiol OE-Di-二-N-辛基醚 | 23.0 | Cognis |
Dehymuls PGPH | 5.0 | Cognis | |
蜂蜡 | 0.5 | Stahl & Pitsch | |
硬脂酸锌 | 0.5 | Whittaker | |
氨基苯甲酸 | 7.0 | ISP | |
胡莫柳酯 | 1.0 | Witco | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
B) | 硫酸镁 | 0.3 | |
甘油96% | 5.0 | Dow Chemical | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 5.0 | VPCS | |
十二烷基亚氨基二丙酸抗坏血酸磷酸酯-30% | 5.0 | VPCS | |
蒸馏水 | q.s.100% | ||
C) | Germall II | 1.0 | Sutton Lab,ISP |
成分 | %WW | 供应商 | |
A) | Cetiol OE-二-N-辛基醚 | 23.0 | Cognis |
Dehymuls PGPH | 5.0 | Cognis | |
蜂蜡 | 0.5 | Stahl & Pitsch | |
硬脂酸锌 | 0.5 | Whittaker | |
苯基苯咪唑磺酸 | 7.0 | ISP | |
Cinoxate | 2.0 | ISP | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
B) | 硫酸镁 | 0.3 | |
甘油96% | 5.0 | Dow Chemical | |
十二烷基亚氨基二丙酸生育酚磷酸酯和十二烷基亚氨基二丙酸抗坏血酸磷酸酯-30% | 10.0 | VPCS | |
蒸馏水 | 44.7 | ||
C) | Germall II | 1.0 | Sutton Lab,ISP |
成分 | %WW | 供应商 | |
A) | Cetiol OE-二-N-辛基醚 | 23.0 | Cognis |
Dehymuls PGPH | 5.0 | Cognis | |
蜂蜡 | 0.5 | Stahl & Pitsch | |
硬脂酸锌 | 0.5 | Whittaker | |
Padimate 0 | 7.0 | ISP | |
二羟苯酮 | 2.0 | ISP | |
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
B) | 硫酸镁 | 0.3 | |
甘油96% | 5.0 | Dow Chemical | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 10.0 | VPCS | |
蒸馏水 | 44.7 | ||
C) | Germall II | 1.0 | Sutton Lab,ISP |
成分 | %WW | 供应商 | |
A) | Cetiol OE-二-N-辛基醚 | 23.0 | Cognis |
Dehymuls PGPH | 5.0 | Cognis | |
蜂蜡 | 0.5 | Stahl & Pitsch | |
硬脂酸锌 | 0.5 | Whittaker | |
辛基对甲氧基肉桂酸 | 7.0 | ISP | |
甲基邻氨基苯甲酸酯 | 2.0 | ||
Dow Corning 200 Fluid-二甲硅油 | 1.0 | Dow Corning | |
B) | 硫酸镁 | 0.3 | |
甘油96% | 5.0 | Dow Chemical | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 10.0 | VPCS | |
蒸馏水 | 44.7 | ||
C) | Germall | 1.0 | Sutton Lab,ISP |
成分 | %WW | 供应商 |
聚甘油-4异硬脂酸和16烷基二甲基硅油Copolol和己基月桂酸酯 | 10.00 | BASF |
Cremophor GS32 | 0.60 | |
甘油基三榆树酸 | 3.00 | |
十六烷基methicone | 2.00 | |
C12-C15烷基苯甲酸盐 | 5.00 | |
Cyclomethicone | 8.85 | Dow Corning |
Z Cote HP-1-氧化锌和Dimethicone | 5.00 | BASF |
苯基Trimethicone | 7.00 | Dow Corning |
Uvinol二氧化钛 | 3.00 | BASF |
黄原胶 | 0.10 | |
甘油 | 3.00 | |
去离子水 | q.s.100% | |
EDTA二钠 | 0.10 | Dow Corning |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 3.33 | VPCS |
十二烷基亚氨基二丙酸抗坏血酸磷酸酯-30% | 6.67 | VPCS |
香味剂、防腐剂 | q.s. |
成分 | %WW | 供应商 |
十二烷基(1)醚硫酸钠 | 5.00 | |
古柯氨基丙基甜菜碱 | 1.50 | |
Merquat 550 | 5.00 | |
Cocamide MEA | 2.00 | |
Cinnamidopropyl trimonium chloride(catc) | 4.00 | |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 2.00 | VPCS |
香味剂、防腐剂 | q.s.as desired | |
去离子水 | q.s.ad 100% |
成分 | %WW | 供应商 |
二硬脂酰二甲基铵盐酸盐 | 2.0 | |
Brij 721-POE 21硬脂酰醚 | 1.0 | Uniqema Americas |
硬脂酰乙醇 | 1.0 | |
十二烷基亚氨基二丙酸生育酚磷酸酯和十二烷基亚氨基二丙酸抗坏血酸磷酸酯-30% | 2.0 | VPCS |
香味剂、防腐剂 | q.s.as desired | |
去离子水 | q.s.ad 100% |
成分 | %WW | 供应商 |
Uvinol MS-40 | 2.00 | BASF |
Masil SF19 | 1.00 | BASF |
DL泛醇 | 2.00 | BASF |
十二烷基亚氨基二丙酸生育酚磷酸酯-30% | 3.00 | VPCS |
Peg 40蓖麻油 | 0.50 | BASF |
柠檬酸 | q.s.as desired | |
防腐剂,香味剂 | q.s.as desired | |
乙醇/水 50/50 | q.s.ad 100% |
组分 | W/w百分比 |
油烯基亚氨基戊酸视黄基磷酸酯Carbomer.RTM.940氢氧化钠调节至需要的pH水 | 151QSQS |
A相 | W/W |
去离子水甘油自由碱形式的精氨酸EDTA三钠Carbomer(Carbopol Ultrez 10)2十二烷基亚氨基二丙酸生育酚磷酸酯1 | 59.00%5.001.740.050.508.64 |
B相 | |
Cetearyl Alcohol(和)Ceteareth-20(Phoenoxol T)3硬脂酸甘油酯(Emerest 2400)4异丙基豆蔻酸酯(Pelemol IPM)3十六烷基己酸酯(Pelemol 168)3异十六烷基榆树酸酯(Pelemol ICB)3油烯基顺芥子酸酯(Cetiol J-600)4 | 2.001.005.003.503.503.00 |
Dimethicone(Dow 200,100 cSt.)5 | 0.50 |
C相 | |
去离子水三乙醇胺(99%) | 5.000.50 |
D相 | |
丙烯基甘油(和)Diazolidinyl尿素(和)Methylparaben(和)Propylparaben(Germaben II)6 | 1.00 |
100.00% |
A相 | W/W |
去离子水甘油EDTA三钠精胺酸作为游离碱卡伯姆(Carbopol Ultrez 10)2Lauryl iminodipropionic Acid Ascorbyl Phosphatel | 65.00%5.000.051.740.502.60 |
B相 | |
Cetearyl Alcohol(和)Ceteareth-20(Phoenoxol T)3硬酯酸甘油醚(Emerest 2400)4豆蔻酸异丙酯(Pelemol IPM)3十六烷基Ethylhexanoate(Pelemol 168)3异十六烷基山嵛酸酯(Pelemol ICB)3Oleyl Erucate(Cetiol J-600)4 | 2.001.005.003.503.503.00 |
二甲基硅油(Dow 200,100 cSt.)5 | 0.50 |
C相 | |
去离子水三乙醇胺(99%) | 5.000.50 |
D相 | |
丙二醇(和)Diazolidinyl Urea(和)对羟基苯甲酸甲酯(和)对羟基苯甲酸丙酯(Germaben II)6 | 1.00 |
100.00% |
成分 | W/w百分比 |
生育三烯酸磷酸酯组氨酸复合物维生素ACarbomer.RTM.940氢氧化钠调节至需要的pH水 | 150.51QSQS |
成分 | W/w百分比 |
十六烷基亚氨基二丙酸P:生育三烯酸P:抗坏血酸磷酸二酯维生素A卡波姆.RTM.940氢氧化钠调节至需要的pH水 | 150.51QSQS |
Claims (58)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30849601P | 2001-07-27 | 2001-07-27 | |
US30850601P | 2001-07-27 | 2001-07-27 | |
US60/308,496 | 2001-07-27 | ||
US60/308,506 | 2001-07-27 | ||
PCT/AU2002/001003 WO2003011303A1 (en) | 2001-07-27 | 2002-07-26 | Dermal therapy using phosphate derivatives of electron transfer agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1547475A true CN1547475A (zh) | 2004-11-17 |
CN1547475B CN1547475B (zh) | 2010-12-15 |
Family
ID=26976276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN028148185A Expired - Fee Related CN1547475B (zh) | 2001-07-27 | 2002-07-26 | 含电子转移试剂的磷酸酯衍生物的皮肤制剂 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8008345B2 (zh) |
EP (1) | EP1420797A4 (zh) |
JP (1) | JP4745608B2 (zh) |
CN (1) | CN1547475B (zh) |
AU (1) | AU2002317053B2 (zh) |
BR (1) | BR0211673A (zh) |
CA (1) | CA2453823C (zh) |
MX (1) | MXPA04000654A (zh) |
WO (1) | WO2003011303A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020093956A1 (zh) * | 2018-11-07 | 2020-05-14 | 扬子江药业集团上海海尼药业有限公司 | 一种含维生素k1 的外用制剂及其制备方法 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
WO2002040034A1 (en) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd. | Complexes of phosphate derivatives |
AU2002350272B1 (en) * | 2001-12-13 | 2003-06-23 | Vital Health Sciences Pty Ltd | Transdermal transport of compounds |
AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
KR20050086954A (ko) * | 2003-01-17 | 2005-08-30 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | 항증식성 화합물 |
DE10307389A1 (de) * | 2003-02-21 | 2004-09-02 | Cognis Deutschland Gmbh & Co. Kg | Anti-Aknemittel |
AU2003901813A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Pharmaceutical derivatives |
AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
JP2005053785A (ja) * | 2003-05-20 | 2005-03-03 | Nippon Menaade Keshohin Kk | 外用剤 |
NZ549567A (en) * | 2004-03-03 | 2009-10-30 | Vital Health Sciences Pty Ltd | Formulations comprising a tocopheryl phosphate tertiary amine alkaloid complex |
JP5198858B2 (ja) * | 2004-08-03 | 2013-05-15 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | 腸内投与のための担体 |
EP1858508A4 (en) * | 2005-03-03 | 2009-01-07 | Vital Health Sciences Pty Ltd | COMPOUNDS HAVING ANTICANCER PROPERTIES |
AU2006257714B2 (en) * | 2005-06-17 | 2011-07-21 | Vital Health Sciences Pty Ltd | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
ES2557475T3 (es) * | 2005-06-17 | 2016-01-26 | Vital Health Sciences Pty Ltd. | Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones |
EP1973547A1 (en) * | 2005-12-23 | 2008-10-01 | Vital Health Sciences Pty Ltd. | Compounds having cytokine modulating properties |
JP2008007428A (ja) * | 2006-06-27 | 2008-01-17 | Showa Denko Kk | 皮膚外用シワ防止剤 |
NL1035426C2 (nl) * | 2008-05-15 | 2009-11-17 | Atp Marketing & Promotion Ag | Farmaceutische samenstellingen voor de behandeling van wratten. |
WO2011075775A1 (en) * | 2009-12-23 | 2011-06-30 | Phosphagenics Limited | Carrier composition |
AU2011213557B2 (en) | 2010-02-05 | 2015-05-07 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
MX2012009068A (es) * | 2010-02-05 | 2012-09-07 | Phosphagenics Ltd | Composicion portadora. |
MX2012011355A (es) | 2010-03-30 | 2012-11-30 | Phosphagenics Ltd | Parche de suministro transdermico. |
FR2969924B1 (fr) * | 2010-12-30 | 2013-11-15 | Lvmh Rech | Composition comprenant un phosphate de tocopherol |
US9561243B2 (en) | 2011-03-15 | 2017-02-07 | Phosphagenics Limited | Composition comprising non-neutralised tocol phosphate and a vitamin A compound |
US9259343B2 (en) | 2012-07-06 | 2016-02-16 | Newman Technologies LLC | Device for mitigating plantar fasciitis |
PT106679B (pt) | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | Formulações tópicas de tetraciclinas, sua preparação e usos |
DE102015217307A1 (de) | 2015-09-10 | 2017-03-16 | Bayerische Motoren Werke Aktiengesellschaft | System zum Laden von Energiespeicherelementen von Elektrofahrzeugen |
CA3007587C (en) | 2015-12-09 | 2023-12-05 | Phosphagenics Limited | Pharmaceutical formulation |
WO2018112512A1 (en) | 2016-12-21 | 2018-06-28 | Phosphagenics Limited | Process |
US12059486B2 (en) | 2021-01-13 | 2024-08-13 | Rodan &Fields, LLC | Cosmetic compositions |
Family Cites Families (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2407823A (en) | 1946-09-17 | Antihemorrhagic esters and methods | ||
US2667479A (en) | 1951-01-30 | 1954-01-26 | Merck & Co Inc | Benzimidazole phosphate |
GB778142A (en) | 1953-11-20 | 1957-07-03 | Leo Ab | High-molecular weight derivatives of hydroxyl group-containing steroids and a method of producing them |
US2913477A (en) | 1957-03-22 | 1959-11-17 | Merck & Co Inc | Antihemorrhagic compounds and processes for preparing the same |
US3127434A (en) | 1959-10-20 | 1964-03-31 | Hoffmann La Roche | Dihydrovitamin k monophosphate compounds and preparation thereof |
US3212901A (en) | 1961-06-07 | 1965-10-19 | Eastman Kodak Co | Stabilized tocopherol concentrates and process for preparing the same |
US3331896A (en) | 1964-09-15 | 1967-07-18 | Gen Aniline & Film Corp | Method of preparing alkali soluble phosphate esters of hydroxylic organic compounds |
DE2526938C2 (de) | 1975-02-14 | 1982-04-22 | F. Hoffmann-La Roche & Co. AG, 4002 Basel | Vitaminpräparate |
US4141938A (en) | 1976-10-07 | 1979-02-27 | Hoechst Aktiengesellschaft | Production of acid orthophosphoric acid ester mixtures |
US4444755A (en) | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
US4299906A (en) | 1979-06-01 | 1981-11-10 | American Hoechst Corporation | Light-sensitive color proofing film with surfactant in a light-sensitive coating |
SU925961A1 (ru) | 1980-08-15 | 1982-05-07 | Московский ордена Трудового Красного Знамени технологический институт пищевой промышленности | Способ получени фосфорилированных глицеридов высших жирных кислот |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
IT1157269B (it) | 1982-03-19 | 1987-02-11 | Seuref Ag | Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica |
CH661438A5 (it) | 1984-04-09 | 1987-07-31 | Seuref Ag | Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. |
US4603142A (en) | 1984-06-01 | 1986-07-29 | Wisconsin Alumni Research Foundation | Cholesterol lowering method of use |
DE3582904D1 (de) | 1984-08-02 | 1991-06-27 | Henkel Corp | Reinigung von tocopherolen durch extraktion. |
JPS6191137A (ja) | 1984-10-11 | 1986-05-09 | Kao Corp | 外用薬剤組成物 |
JPH0781138B2 (ja) | 1986-12-02 | 1995-08-30 | 株式会社資生堂 | 抗酸化剤 |
DE3702766A1 (de) | 1987-01-30 | 1988-08-11 | Henkel Kgaa | Verfahren zur herstellung und isolierung von monoalkylphosphorsaeureestern |
JP3070744B2 (ja) | 1987-04-10 | 2000-07-31 | 株式会社日立製作所 | ベクトル処理装置 |
US4952495A (en) | 1987-06-08 | 1990-08-28 | Eastman Kodak Company | Hydrolyzable compounds which release electron transfer agents and analytical use of same |
PH25859A (en) | 1988-01-11 | 1991-12-02 | Takeda Chemical Industries Ltd | Composition for treatment of ischemic disorder |
US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
DE3813624A1 (de) | 1988-04-22 | 1989-11-02 | Basf Ag | Verfahren zur herstellung von d-(alpha)-tocopherol aus natuerlichen vorprodukten |
CA2007643A1 (en) | 1989-02-01 | 1990-08-01 | Donald S. Karanewsky | Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination |
US6028105A (en) * | 1989-04-06 | 2000-02-22 | Nigra; Thomas P. | Topical drug delivery composition and method |
US5053222A (en) | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
US5094848A (en) | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
DE3927113C2 (de) | 1989-08-17 | 1993-11-25 | Dolorgiet Gmbh & Co Kg | Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung |
JP2854631B2 (ja) | 1989-11-21 | 1999-02-03 | 千寿製薬株式会社 | 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤 |
IT1236843B (it) | 1989-11-22 | 1993-04-21 | Simes | Processo per la preparazione di 4-0-fosfati di dopamina o suoi derivati |
JPH03206089A (ja) | 1990-01-05 | 1991-09-09 | Eisai Co Ltd | 新規ビタミンe誘導体及びその製造方法 |
US5374645A (en) | 1990-01-22 | 1994-12-20 | Ciba-Geigy Corporation | Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol |
FR2657526B1 (fr) * | 1990-01-31 | 1994-10-28 | Lvmh Rech | Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues. |
US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
US5114957A (en) | 1990-05-08 | 1992-05-19 | Biodor U.S. Holding | Tocopherol-based antiviral agents and method of using same |
SE9003665D0 (sv) | 1990-11-16 | 1990-11-16 | Kabivitrum Ab | Morphine prodrugs |
JP3035742B2 (ja) * | 1990-11-30 | 2000-04-24 | 昭和電工株式会社 | 化粧品 |
FR2679904A1 (fr) * | 1991-08-01 | 1993-02-05 | Lvmh Rech | Utilisation d'un phosphate de tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, ou pharmaceutiques et compositions ainsi obtenues. |
US5643597A (en) | 1991-08-01 | 1997-07-01 | Lvmh Recherche | Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained |
EP0535283A1 (en) | 1991-10-02 | 1993-04-07 | Merrell Dow Pharmaceuticals Inc. | Cardioprotective tocopherol analogs |
US5474891A (en) | 1991-10-30 | 1995-12-12 | Thomas Jefferson University | Plasma-based platelet concentrate preparations with additive |
JPH07504887A (ja) | 1991-11-22 | 1995-06-01 | リポジェニックス,インコーポレイテッド | トコトリエノールおよびトコトリエノール様化合物ならびにこれらを使用する方法 |
US5282312A (en) | 1991-12-31 | 1994-02-01 | Tessera, Inc. | Multi-layer circuit construction methods with customization features |
JPH05286848A (ja) | 1992-04-10 | 1993-11-02 | Senju Pharmaceut Co Ltd | 浴用剤 |
GB9212450D0 (en) | 1992-06-11 | 1992-07-22 | Indena Spa | New derivatives of non-steroidal anti-inflammatory,analgesic and/or antipyretic substances,their use and pharmaceutical formulations containing them |
US5741518A (en) | 1992-08-03 | 1998-04-21 | L'oreal | Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
US5773457A (en) | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
AU5171293A (en) | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
US5348357A (en) | 1992-12-24 | 1994-09-20 | General Motors Corporation | Vehicle closure latch having plastic coated ratchet |
US6384043B1 (en) | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
TW252918B (zh) | 1993-03-31 | 1995-08-01 | Senju Pharma Co | |
GB9318271D0 (en) | 1993-09-03 | 1993-10-20 | Scotia Holdings Plc | Tocopherols |
CA2129509A1 (en) | 1993-09-10 | 1995-03-11 | Kazumi Ogata | Pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis |
CA2176743A1 (en) | 1993-11-27 | 1995-06-01 | Brian Christopher Challis | Compositions comprising iminium ion scavengers and/or nitrite scavengers |
JPH07196516A (ja) | 1993-12-29 | 1995-08-01 | Senju Pharmaceut Co Ltd | 痔疾患治療剤 |
JPH07207298A (ja) * | 1994-01-21 | 1995-08-08 | Nippon Oil & Fats Co Ltd | 洗浄剤組成物 |
FR2715565B1 (fr) | 1994-01-31 | 1996-03-15 | Oreal | Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation. |
EP0669132A1 (en) | 1994-02-23 | 1995-08-30 | van der Kraaij, Antonius Marinus Maria | Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis |
CA2145229A1 (en) | 1994-03-29 | 1995-09-30 | Tetsuya Toge | Suppressory compositions against hepatic metastases of tumors |
US5554781A (en) | 1994-03-30 | 1996-09-10 | Reierson; Robert L. | Monoalkyl phosphonic acid ester production process |
JPH07277988A (ja) | 1994-04-05 | 1995-10-24 | Senju Pharmaceut Co Ltd | 局所用掻痒除去、治療剤 |
TW287103B (zh) * | 1994-04-22 | 1996-10-01 | Senju Pharma Co | |
JP3362501B2 (ja) | 1994-04-28 | 2003-01-07 | 千寿製薬株式会社 | 角膜障害治療剤 |
JP3396953B2 (ja) | 1994-05-10 | 2003-04-14 | 千寿製薬株式会社 | 網膜疾患予防・治療剤 |
US5589504A (en) | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
CA2152693A1 (en) | 1994-08-05 | 1996-02-06 | Kazumi Ogata | Therapeutic composition for pancreatitis |
IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
JPH0873338A (ja) * | 1994-09-02 | 1996-03-19 | Noevir Co Ltd | 皮膚外用剤 |
HU215966B (hu) | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum |
DE4444238A1 (de) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden |
FR2730928B1 (fr) | 1995-02-23 | 1997-04-04 | Oreal | Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique |
KR100387156B1 (ko) | 1995-04-21 | 2003-10-11 | 세키스이가가쿠 고교가부시키가이샤 | 피부질환치료용외용제 |
JPH08311489A (ja) * | 1995-05-19 | 1996-11-26 | Nippon Oil & Fats Co Ltd | 洗浄剤組成物 |
JP3622267B2 (ja) * | 1995-05-31 | 2005-02-23 | 日本油脂株式会社 | 洗浄剤組成物 |
US5607968A (en) | 1995-06-07 | 1997-03-04 | Avon Products, Inc. | Topical alkyl-2-O-L-ascorbyl-phosphates |
KR100423458B1 (ko) * | 1995-07-12 | 2004-05-17 | 가부시키가이샤 시세이도 | 피부외용제 |
EP0798305B1 (en) * | 1995-10-17 | 2007-10-03 | Showa Denko Kabushiki Kaisha | High-purity tocopherol phosphates, process for the preparation thereof, method for analysis thereof, and cosmetics |
FR2741263B1 (fr) | 1995-11-22 | 1997-12-26 | Oreal | Composition comprenant une dispersion aqueuse de vesicules lipidiques encapsulant un filtre uv a fonction acide et utilisations en application topique |
ATE335492T1 (de) | 1996-03-27 | 2006-09-15 | Inspire Pharmaceuticals Inc | Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen |
US6077828A (en) | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
US5885595A (en) | 1996-05-13 | 1999-03-23 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic composition with a retinol fatty acid ester |
JPH09309813A (ja) * | 1996-05-22 | 1997-12-02 | Nonogawa Shoji Kk | 皮膚外用剤 |
CA2209690A1 (en) | 1996-07-31 | 1998-01-31 | Sachiko Matsuura | Therapeutic drug for acne vulgaris |
JPH1067639A (ja) | 1996-08-26 | 1998-03-10 | Shiseido Co Ltd | ビタミンe−ビタミンcリン酸ジエステル/シクロデキストリン包接物及び該包接物を配合した皮膚外用剤 |
JPH10155429A (ja) | 1996-11-27 | 1998-06-16 | Showa Denko Kk | 動物に対するビタミンe供給方法および動物用トコフェロールリン酸エステル又はその塩類組成物 |
US6022867A (en) | 1996-11-27 | 2000-02-08 | Showa Denko Kabushiki Kaisha | Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6727280B2 (en) | 1997-01-07 | 2004-04-27 | Sonus Pharmaceuticals, Inc. | Method for treating colorectal carcinoma using a taxane/tocopherol formulation |
US6932975B2 (en) | 1997-01-29 | 2005-08-23 | Kao Corporation | Cosmetic composition comprising a phosphoric triester and a skin activating component |
US5804168A (en) * | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
WO1998040069A2 (en) | 1997-03-13 | 1998-09-17 | Hexal Ag | Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations |
US7179486B1 (en) | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
FR2764891B1 (fr) | 1997-06-04 | 2001-04-13 | Pacific Corp | Derive de l'acide l-ascorbique stable dans l'eau, procede pour sa preparation et composition cosmetique de blanchiment de la peau le contenant |
US5928631A (en) * | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US5776915A (en) | 1997-08-12 | 1998-07-07 | Clarion Pharmaceuticals Inc. | Phosphocholines of retinoids |
US6096326A (en) * | 1997-08-15 | 2000-08-01 | Scandinavian-American Import/Export Corporation | Skin care compositions and use |
JPH11199465A (ja) * | 1998-01-07 | 1999-07-27 | Nonogawa Shoji Kk | 皮膚外用剤 |
WO1999039716A1 (fr) | 1998-02-03 | 1999-08-12 | Senju Pharmaceutical Co., Ltd. | Substances preventives et medicaments destines aux maladies neurodegeneratives |
US6461623B2 (en) * | 1998-04-13 | 2002-10-08 | Kao Corporation | Cosmetic composition |
JP4208209B2 (ja) | 1998-06-22 | 2009-01-14 | フジノン株式会社 | コリメータレンズおよびこれを用いた光走査装置 |
US6121249A (en) | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
WO2000001351A1 (en) | 1998-07-07 | 2000-01-13 | Transdermal Technologies, Inc. | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
IL142082A (en) | 1998-09-23 | 2005-12-18 | Res Dev | Tocoflowers, tocotrinols, derivatives as a novel and other side-chain and their uses |
US6770672B1 (en) | 1998-09-23 | 2004-08-03 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
US6703384B2 (en) | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
US6048891A (en) | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
AUPP829399A0 (en) | 1999-01-25 | 1999-02-18 | Swig Pty Ltd | Recovery for chroman derivatives |
AUPQ037499A0 (en) | 1999-05-14 | 1999-06-10 | Swig Pty Ltd | Improved process for phosphorylation and compounds produced by this method |
JP2000212082A (ja) * | 1999-01-26 | 2000-08-02 | Showa Denko Kk | 皮膚用剤 |
US6156354A (en) | 1999-01-29 | 2000-12-05 | Brandeis University | Hyper-absorption of vitamin E dispersed in milks |
US6184247B1 (en) | 1999-05-21 | 2001-02-06 | Amway Corporation | Method of increasing cell renewal rate |
AU5594700A (en) | 1999-06-01 | 2000-12-18 | Ocean Spray Cranberries, Inc. | Cranberry seed oil extract and compositions containing components thereof |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6423742B1 (en) | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
KR20020059415A (ko) | 1999-09-27 | 2002-07-12 | 스티븐 씨. 큐웨이 | 토콜-가용성 치료요법제 |
JP2004504268A (ja) | 2000-02-11 | 2004-02-12 | リサーチ ディベロップメント ファンデーション | トコフェロール、トコトリエノール、その他のクロマン、及びそれらの側鎖誘導体とその利用法 |
US20030035812A1 (en) | 2000-02-29 | 2003-02-20 | Shinobu Ito | Immune enhancement compositions and use thereof |
US6346544B2 (en) | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
JP2001247585A (ja) | 2000-03-03 | 2001-09-11 | Nof Corp | トコフェロール誘導体、その中間体、その製造方法及び用途 |
US6444220B2 (en) | 2000-03-16 | 2002-09-03 | Teresa S. Wiley | Method and compositions for changing the contour of skin |
US6361800B1 (en) | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
US6485950B1 (en) | 2000-07-14 | 2002-11-26 | Council Of Scientific And Industrial Research | Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions |
KR100365070B1 (ko) | 2000-08-29 | 2002-12-16 | 주식회사 태평양 | 토코페롤 유도체 및 그의 제조방법 |
JP4818500B2 (ja) | 2000-09-05 | 2011-11-16 | 株式会社ペンタプラストア | トコトリエノール誘導体及びその製造方法 |
US20030206972A1 (en) | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
WO2002040034A1 (en) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd. | Complexes of phosphate derivatives |
WO2002040033A1 (en) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd | Formulation containing phosphate derivatives of electron transfer agents |
AUPR549901A0 (en) | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
US20020132845A1 (en) | 2000-12-15 | 2002-09-19 | Miller Guy Michael | Compositions and methods for the prevention and treatment of tissue ischemia |
US20020151467A1 (en) | 2000-12-21 | 2002-10-17 | Leung Frank K. | Methods and compositions for oral insulin delivery |
US20020131994A1 (en) | 2001-01-10 | 2002-09-19 | Schur Henry B. | Non-irritating formulation for the transdermal delivery of substances |
US6849271B2 (en) | 2001-04-27 | 2005-02-01 | Verion, Inc. | Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods |
KR100394770B1 (ko) | 2001-06-05 | 2003-08-14 | 주식회사 태평양 | 토코페롤 유도체를 이용하여 나노유화입자를 안정화시키는방법 및 나노유화입자를 함유하는 피부 외용제 조성물 |
AUPR684801A0 (en) | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
AU2002951045A0 (en) | 2002-08-27 | 2002-09-12 | Vital Health Sciences Pty Ltd | Method of supplementing nascent endogenous storage forms |
JP2003128531A (ja) | 2001-10-17 | 2003-05-08 | Nonogawa Shoji Kk | 皮膚外用剤 |
AU2002350272B1 (en) | 2001-12-13 | 2003-06-23 | Vital Health Sciences Pty Ltd | Transdermal transport of compounds |
US7074825B2 (en) | 2002-03-07 | 2006-07-11 | Huanbiao Mo | Composition and method for treating cancer |
AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
US20040067890A1 (en) | 2002-10-04 | 2004-04-08 | Gupta Shyam K. | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions |
US6645514B1 (en) | 2002-12-19 | 2003-11-11 | Access Business Group International, Llc | Increasing skin cell renewal with water-soluble Vitamin E |
KR20050086954A (ko) | 2003-01-17 | 2005-08-30 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | 항증식성 화합물 |
US7033998B2 (en) | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
AU2003901812A0 (en) | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
AU2003901815A0 (en) | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
AU2003901813A0 (en) | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Pharmaceutical derivatives |
NZ549567A (en) | 2004-03-03 | 2009-10-30 | Vital Health Sciences Pty Ltd | Formulations comprising a tocopheryl phosphate tertiary amine alkaloid complex |
JP5198858B2 (ja) | 2004-08-03 | 2013-05-15 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | 腸内投与のための担体 |
EP1858508A4 (en) | 2005-03-03 | 2009-01-07 | Vital Health Sciences Pty Ltd | COMPOUNDS HAVING ANTICANCER PROPERTIES |
US20090239827A1 (en) | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
JP4270212B2 (ja) | 2005-03-29 | 2009-05-27 | セイコーエプソン株式会社 | 基板間隔調整装置、基板間隔調整方法、および液晶表示装置の製造方法 |
ES2557475T3 (es) | 2005-06-17 | 2016-01-26 | Vital Health Sciences Pty Ltd. | Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones |
EP1973547A1 (en) | 2005-12-23 | 2008-10-01 | Vital Health Sciences Pty Ltd. | Compounds having cytokine modulating properties |
-
2002
- 2002-07-26 JP JP2003516533A patent/JP4745608B2/ja not_active Expired - Lifetime
- 2002-07-26 EP EP02744952A patent/EP1420797A4/en not_active Withdrawn
- 2002-07-26 CA CA2453823A patent/CA2453823C/en not_active Expired - Lifetime
- 2002-07-26 US US10/485,196 patent/US8008345B2/en active Active
- 2002-07-26 AU AU2002317053A patent/AU2002317053B2/en not_active Expired
- 2002-07-26 WO PCT/AU2002/001003 patent/WO2003011303A1/en active IP Right Grant
- 2002-07-26 MX MXPA04000654A patent/MXPA04000654A/es active IP Right Grant
- 2002-07-26 BR BR0211673-1A patent/BR0211673A/pt active Search and Examination
- 2002-07-26 CN CN028148185A patent/CN1547475B/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020093956A1 (zh) * | 2018-11-07 | 2020-05-14 | 扬子江药业集团上海海尼药业有限公司 | 一种含维生素k1 的外用制剂及其制备方法 |
US11213493B2 (en) | 2018-11-07 | 2022-01-04 | Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd. | Topical preparation containing vitamin K1 and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2004538308A (ja) | 2004-12-24 |
CN1547475B (zh) | 2010-12-15 |
US20040253318A1 (en) | 2004-12-16 |
JP4745608B2 (ja) | 2011-08-10 |
AU2002317053B2 (en) | 2004-08-05 |
WO2003011303A1 (en) | 2003-02-13 |
BR0211673A (pt) | 2004-07-13 |
CA2453823C (en) | 2010-12-21 |
EP1420797A1 (en) | 2004-05-26 |
MXPA04000654A (es) | 2004-03-19 |
US8008345B2 (en) | 2011-08-30 |
CA2453823A1 (en) | 2003-02-13 |
EP1420797A4 (en) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1547475A (zh) | 采用电子转移试剂的磷酸酯衍生物进行皮肤治疗 | |
CN1230148C (zh) | 包含n-乙烯基咪唑聚合物或共聚物和氧化敏感亲水有效成分的组合物的化妆用途 | |
CN1262274C (zh) | 磷酸盐衍生物复合物 | |
TWI353861B (zh) | ||
EP0646370B1 (fr) | Compositions cosmétiques et dermatologiques associant céramides et acide linoléique, leur préparation | |
CN102046178B (zh) | 用于皮肤护理的组合物和方法 | |
CN1943545A (zh) | 一种化妆品组合物及其制备方法和应用 | |
CN1155376C (zh) | 9-顺-视黄酸及其盐和酯的药物用途 | |
CN1522150A (zh) | 含有洋葱提取物的含脂肪(油)制剂及其制备和对于护理、预防或治疗受损皮肤组织特别是瘢痕的用途 | |
US9855210B2 (en) | Topical formulations containing palm pollen | |
CN1753968A (zh) | 抗氧化组合物以及外用组合物 | |
CN1893911A (zh) | 含有四肽和三肽混合物的配方 | |
CN1285751A (zh) | 用于治疗和预防皮肤光损伤的抗诱变剂组合物 | |
CN1310032C (zh) | 用于改善瘙痒、皮肤粗糙或皮肤敏感或用于增白的药物 | |
CN1315940A (zh) | 半胱氨酸衍生物 | |
CN1281354A (zh) | 用于调节皮肤的油性/光泽性外表的局部组合物 | |
JPH0517363A (ja) | 抗炎症剤及びそれを含有する化粧料 | |
CN111631985A (zh) | 一种含叶酸的抗皱组合物、眼霜及其制备方法 | |
US11213472B2 (en) | VEGFC production promoter | |
CN114588068A (zh) | 具有皮肤美白淡斑功效的组合物 | |
US20200405621A1 (en) | Skin Care Composition | |
JP4869751B2 (ja) | サンバーンセル形成抑制剤及びdna損傷修復促進剤 | |
CN1627941A (zh) | 用于治疗皮脂溢的含有4-羟基-5-甲氧基-4-[2-甲基-3-(3-甲基-2-丁烯基)-2-氧杂环丙基]-1-氧杂螺[2,5]辛-6-酮的药物组合物 | |
US20210228469A1 (en) | Skin Care Composition | |
US20180280287A1 (en) | Method and composition for a sacha inchi perennial plant extract based health and beauty aid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CI01 | Publication of corrected invention patent application |
Correction item: Priority Correct: 1)60/308,496;20010727;US |2)60/308,506;20010727;US Number: 50 Volume: 26 |
|
CI02 | Correction of invention patent application |
Correction item: Priority Correct: 1)60/308,496;20010727;US |2)60/308,506;20010727;US Number: 50 Page: The title page Volume: 26 |
|
ERR | Gazette correction |
Free format text: CORRECT: PRIORITY; FROM: NONE TO: 1)60 08,496;20010727;US 2)60 08,506;20010727;US |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101215 Termination date: 20130726 |